Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.
Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function. This simplifies dosing, with a requirement for only once-daily administration and a lack of drug-drug interactions in patients who require multiple medications.
De Bellis
Pasquale
P
UOC Institute of Anesthesia and Resuscitation, Department of Cardiac-Nephrology, Azienda Ospedaliera Universitaria S. Martino di Genova, Genoa, Italy.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000517:prevention & control; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D054714:Echinocandins / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin